Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:359204.
doi: 10.1155/2012/359204. Epub 2012 Jun 10.

Exercise intolerance in pulmonary arterial hypertension

Robin M Fowler  1 , Kevin R Gain, Eli Gabbay
Affiliations

Exercise intolerance in pulmonary arterial hypertension

Robin M Fowler et al. Pulm Med. 2012.

Abstract

Pulmonary arterial hypertension (PAH) is associated with symptoms of dyspnea and fatigue, which contribute to exercise limitation. The origins and significance of dyspnea and fatigue in PAH are not completely understood. This has created uncertainly among healthcare professionals regarding acceptable levels of these symptoms, on exertion, for patients with PAH. Dysfunction of the right ventricle (RV) contributes to functional limitation and mortality in PAH; however, the role of the RV in eliciting dyspnea and fatigue has not been thoroughly examined. This paper explores the contribution of the RV and systemic and peripheral abnormalities to exercise limitation and symptoms in PAH. Further, it explores the relationship between exercise abnormalities and symptoms, the utility of the cardiopulmonary exercise test in identifying RV dysfunction, and offers suggestions for further research.

PubMed Disclaimer

References

    1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. Circulation. 2009;119(16):2250–2294. - PubMed
    1. Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry. Chest. 2011;140(1):19–26. - PMC - PubMed
    1. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. European Heart Journal. 2009;30(4):394–403. - PMC - PubMed
    1. Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compelling evidence of long-term outcomes in pulmonary arterial hypertension?: a clinical perspective. Journal of the American College of Cardiology. 2011;57(9):1053–1061. - PubMed
    1. Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of Life in Pulmonary Arterial Hypertension: improvement and Maintenance With Bosentan. Journal of Heart and Lung Transplantation. 2007;26(2):181–187. - PubMed

LinkOut - more resources